Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-000804
Abstract: Background Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose dependence… read more here.
Keywords: initial dose; oncolytic myxoma; myxoma virus; treated tumors ... See more keywords